NGL Fine-Chem Limited (NGLFINE.NS) NSE
2,569.90
-84.6(-3.19%)
Currency In INR
- General
- Statistics
- Historical Data
- Profile
- Financials
2,569.90
-84.6(-3.19%)
Currency In INR
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
682
First IPO Date
July 08, 2022
| Name | Title | Pay | Year Born |
| Rahul Jayant Nachane | Chief Executive Officer, MD, Chief Ethics Counsellor & Executive Director | 18.35M | 1964 |
| Rajesh Narayan Lawande | Whole Time Director & Chief Financial Officer | 18.21M | 1976 |
| Shivam Gharat | Company Secretary & Compliance Officer | 0 | N/A |
| Ahaan Nachane | Vice President | 0 | N/A |
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. It offers active pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, and marbofloxacin for animal health applications; and nitazoxanide, atovaquone, and ranolazine for human health applications. The company also provides various intermediate products; and finished dosage forms in granules and tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.